Pilocytic astrocytoma
MONDO:0016691Pilocytic astrocytoma is a rare subtype of low-grade glioma of the central nervous system characterized by a well circumscribed, often cystic, brain tumor with a discrete mural nodule and long, hair-like projections that extend from the neoplastic astrocytes. Depending on the primary localization and the size of the tumor, patients can present with signs of raised intracranial pressure (headache, vomiting, papilledema), blurred vision, decreased visual acuity, ataxia and/or nystagmus, among others. It is most commonly located in the cerebellum, but occurrence in the hypothalamus, brain stem, optic chiasma, and hemispheres has also been reported.
Also known as: astrocytoma, benign, astrocytoma, pilocytic, benign, grade I astrocytic neoplasm, grade I astrocytic tumor, grade I astrocytic tumour, grade I astrocytoma, pilocytic astrocytoma
1459 clinical trials for this condition and its sub-types, 12 tagged with Pilocytic astrocytoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Pilocytic astrocytoma
-
Pilomyxoid astrocytoma 5 trials
-
Childhood pilocytic astrocytoma 1 trial
1 sub-type
- Juvenile pilocytic astrocytoma 0 trials
-
Cerebellar pilocytic astrocytoma 0 trials
-
New drug could replace chemo for kids with brain tumor
Disease control Recruiting nowThis study tests whether a targeted drug called selumetinib works as well as standard chemotherapy (carboplatin and vincristine) for children and young adults with a slow-growing brain tumor called low-grade glioma. Participants must be 2 to 21 years old and have a tumor without …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New pill shows promise in early brain tumor trial
Disease control Recruiting nowThis early-stage study tests an oral drug called ONC206 in adults with brain tumors that have come back. The main goal is to find the safest dose and check for side effects. About 102 participants will take the drug once or several times a week.
Phase 1 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC